New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

Seagate Technology Holdings (NASDAQ:STX) provides data storage technology and infrastructure solutions internationally. It ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

Enhertu, for instance ... At present, most ADCs are used at the maximum dose a person can tolerate. That might not be true with future versions. When developing a medication, whether it’s ...

Enhertu (trastuzumab deruxtecan) in a subset of early-stage breast cancer patients. The phase 3 DESTINY-Breast11 trial has been evaluating the drug followed by paclitaxel, trastuzumab and pertuzumab ...

four cycles of Enhertu followed by four cycles of THP; or four cycles of ddAC (dose-dense doxorubicin and cyclophosphamide) followed by four cycles of THP. The primary endpoint of DESTINY-Breast11 ...

May 07, 2025--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab ... rate versus standard of care (dose-dense doxorubicin ...

four cycles of ENHERTU followed by four cycles of THP; or four cycles of ddAC (dose-dense doxorubicin and cyclophosphamide) followed by four cycles of THP. The primary endpoint of DESTINY-Breast11 ...

Enhertu showed significant improvement in pathologic complete ... improvement in pathologic complete response rates compared with standard-of-care treatment (dose-dense doxorubicin and ...